SecBot SecBot
8-K ·Filed Nov 10, 2026

OCGN

Ocugen, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6d 18h ago SEC0001104659-26-124836
8-K material event: Items 1.01
Actionable Insight • Neutral

The deal provides non-dilutive funding and a path to commercial reach in Asia-Pacific, but all payments are contingent on clinical success and regulatory approval. Monitor the Phase 3 topline data readout in Q1 2027 as the next major catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

OCU400

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
Potential FDA approval in 2027-2028 if Phase 3 succeeds and BLA submission (targeted Q3 2026 rolling) is accepted.
Next catalyst
None dated

What to watchWatch for the rolling BLA submission in Q3 2026 as a validation event and the Phase 3 topline readout in Q1 2027 as the primary binary catalyst. The stock has strong institutional accumulation and analyst support (9 Buy, mean PT ~$11.43 vs ~$1.43), but remains pre-revenue with high dilution risk from $130M convertible notes. The Phase 1/2 data was encouraging, durability and a gene-agnostic approach differentiate OCU400 from the only approved therapy, Luxturna.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$0.9500
T+0 close · Nov 10, 2026 · via day close
Latest settled
+1.09%
T+1 · $0.9604
Vs SPY
−0.22%
α at T+1
Next horizon
T+5
in 4h
  1. T+0 · Nov 10 $0.9500entry
  2. T+1 · 6d ago +1.09%α −0.22% · $0.9604
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ocugen entered into an exclusive license agreement with Celairis Therapeutics for OCU400, a modifier gene therapy for retinitis pigmentosa, in Australia, New Zealand, and ASEAN markets. Ocugen receives up to $7.1 million in upfront and milestone payments, a high single-digit royalty on net sales, and 50% of gross profits from the territory. The deal expands Ocugen's global access strategy for OCU400 ahead of Phase 3 topline data expected in Q1 2027.

Key Financial Metrics

Deal Value
$7.1M
Deal Type
license

Key Facts

  • Ocugen granted Celairis an exclusive license to commercialize OCU400 in Australia, New Zealand, and ASEAN markets.
  • Ocugen receives up to $7.1 million in upfront and milestone payments, including $6.1 million tied to positive Phase 3 topline results and an upfront fee.
  • A $1.0 million milestone is payable upon Australian TGA approval of OCU400.
  • Ocugen receives a high single-digit percentage royalty on net sales and 50% of gross profits from OCU400 net sales in the territory.
  • Ocugen retains sole right to manufacture OCU400 in the territory; a supply agreement is expected within 90 days.
  • Phase 3 LiMeliGhT trial topline data for OCU400 is expected in Q1 2027.
  • This is Ocugen's third strategic regional partnership for OCU400.

Financial Impact

Up to $7.1 million in upfront and milestone payments, plus high single-digit royalty on net sales and 50% of gross profits from the territory.

revenuecash_flows

Risk Factors

  • All milestone payments depend on positive Phase 3 results and regulatory approvals, which are uncertain.
  • OCU400 has not been approved in any jurisdiction; the territory license has no value if the drug fails to gain approval.
  • The supply agreement is not yet finalized and may not be entered into.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-124836
Document: tm2629434d1_ex99-1.htm0001104659-26-124836
Document: 0001104659-26-124836-index-headers.html0001104659-26-124836
Document: 0001104659-26-124836-index.html0001104659-26-124836
Document: 0001104659-26-124836.txt0001104659-26-124836

Track record

23 reports on OCGN

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago 8-K Neutral 4/10 Viewing Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  2. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
  3. Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  4. Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  6. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
  7. Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  8. Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
  9. Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026